(October 10, 2022, 1:45 PM EDT) -- ALEXANDRIA, Va. — A recent petition for inter partes review (IPR) of a patented oral dosage formulation used to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome (IBS) should be rejected, Bausch Health Ireland Limited told the Patent Trial and Appeal Board Oct. 7....